This issue of PET Clinics focuses on Radiotracers, and is edited by Drs. Neil Vasdev and Abass Alavi. Articles will include: PET/CT detection of HER2-positive metastases in patients with 89Zr-DFO-trastuzumab; uPAR-PET with 68Ga-NOTA-AE105: first clinical experience with a novel PET ligand; 64Cu-FBP8: A fibrin-targeted probe for imaging of thrombus; Imaging of synaptic density in the brain via synaptic vesicle glycoprotein 2A (SV2A) with a novel biomarker [11C]UCB-J; Neuroimaging of stress sensitive and neuroinflammatory targets in mood disorders; Impact of MR-based PET motion correction on the quantification of PET kinetic parameters in simultaneous cardiac PET-MR; Multimodal studies of the contributions of amyloid and tau burden to neurodegeneration in AD, FTD and Non-AD tauopathies; Imaging of prostate-specific membrane antigen (PSMA) using [18F]DCFPyL; Ga-68 GRPR antagonist imaging; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. CME Accreditation Page - p. ix 8. Preface - p. xi 9. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis - p. 269 10. Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL - p. 289 11. Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology - p. 297 12. Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand - p. 311 13. Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging - p. 321 14. PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers - p. 329 15. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias - p. 351 16. Novel Phenotypes Detectable with PET in Mood Disorders: Elevated Monoamine Oxidase A and Translocator Protein Level - p. 361
No hay muestra disponible
No hay ficha técnica disponible
This issue of PET Clinics focuses on Radiotracers, and is edited by Drs. Neil Vasdev and Abass Alavi. Articles will include: PET/CT detection of HER2-positive metastases in patients with 89Zr-DFO-trastuzumab; uPAR-PET with 68Ga-NOTA-AE105: first clinical experience with a novel PET ligand; 64Cu-FBP8: A fibrin-targeted probe for imaging of thrombus; Imaging of synaptic density in the brain via synaptic vesicle glycoprotein 2A (SV2A) with a novel biomarker [11C]UCB-J; Neuroimaging of stress sensitive and neuroinflammatory targets in mood disorders; Impact of MR-based PET motion correction on the quantification of PET kinetic parameters in simultaneous cardiac PET-MR; Multimodal studies of the contributions of amyloid and tau burden to neurodegeneration in AD, FTD and Non-AD tauopathies; Imaging of prostate-specific membrane antigen (PSMA) using [18F]DCFPyL; Ga-68 GRPR antagonist imaging; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. viii 7. CME Accreditation Page - p. ix 8. Preface - p. xi 9. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis - p. 269 10. Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL - p. 289 11. Theranostic Prospects of Gastrin-Releasing Peptide Receptor–Radioantagonists in Oncology - p. 297 12. Urokinase Plasminogen Activator Receptor–PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand - p. 311 13. Magnetic Resonance–based Motion Correction for Quantitative PET in Simultaneous PET-MR Imaging - p. 321 14. PET Imaging for Early Detection of Alzheimer’s Disease: From Pathologic to Physiologic Biomarkers - p. 329 15. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non–Alzheimer Disease Dementias - p. 351 16. Novel Phenotypes Detectable with PET in Mood Disorders: Elevated Monoamine Oxidase A and Translocator Protein Level - p. 361
No hay muestra disponible
No hay ficha técnica disponible
